U.S. stocks surged Friday, with the Dow hitting an intraday record, joining a rally in Asian and European shares that was spurred by the Bank of Japan’s decision to unexpectedly expand its stimulus measures.

Friday’s rally caps a wild month for U.S. stocks. Fears about a sharp slowdown in global growth, particularly in Europe and Asia, whipsawed the market in early October, sending stocks on their most volatile stretch since 2011. The Dow Jones Industrial Average headed into the month slightly above 17,000, but by mid-October the index had fallen more than 5%, taking it into negative territory for the year.

AbbVie Inc. (NYSE:ABBV) surges to a new 52-week high after posting better than expected results in its first earnings report since its mega-merger with Shire fell apart.ABBV also raised its EPS outlook for the year to $3.25-$3.27, up from its prior view for $3.06-$3.16, not including any potential sales from its hepatitis C virus treatment, which is expected to receive approval from U.S. regulators before year's end.

Digirad Corporation (NASDAQ:DRAD) Q3 results: Revenues: $13.9M (+12.1%); COGS: $9M (+4.7%); Operating Expenses: $3.2M (+14.3%); Operating Loss: ($16.8M) (-147.1%); Net Loss: ($10M) (-56.3%); Loss Per Share: ($0.26) (-4.0%).

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Q3 results: Revenues: $633K (+216.5%); R&D Expense: $9.7M (+56.5%); SG&A: $2.8M (-9.7%); Operating Loss: $(11.9M) (-30.8%); Net Loss: $(6.1)M (+63.5%); EPS: $-0.06 (+70.0%); Quick Assets: $46.1M (-32.4%).

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) plummets to 52-week lows after reporting a wider than expected Q3 loss and issuing downside guidance for FY 2014.AEGR now sees 2014 revenues of $150M-$160M from its prior range of $180M-$200M and below $172M analyst consensus estimate, after Q3 sales of its flagship Juxtapid drug fell $5M short of expectations at $44M.

Four days after getting crushed on news the FDA wants additional data on its eteplirsen muscular dystrophy drug, Sarepta Therapeutics Inc. (NASDAQ:SRPT) is bouncing in response to an FDA statement clarifying its stance.The FDA notes its concerns that "the methods used to measure [muscle protein] dystrophin were not adequately robust to support an NDA submission" for eteplirsen, and that it "provided Sarepta with detailed recommendations on how to improve these dystrophin analyses."